Movement Alert｜BIOCYTOGEN-B Rises 9.63% in Regular Trading, AI Pharma Catalysts and Robust H1 Earnings Drive Rally

Market Focus09-21 14:13

On September 21, BIOCYTOGEN-B rose 9.63% in regular trading, trading at HKD 67.1/share, with turnover of HKD 205 million. The rally was fueled by intensifying AI drug discovery policy catalysts and the resonance of the company's outstanding first-half financial performance.

On the industry front, AI pharma policy and partnership catalysts have landed in rapid succession, with CXO sector sentiment firmly trending upward. Broker research notes that H1 domestic CXO sector revenue and net profit grew 24.5% and 52.7% year-over-year respectively, with order backlogs and new signings recovering broadly while leading firms raised full-year guidance.

On the earnings front, BIOCYTOGEN-B reported H1 revenue of RMB 941 million, up 51.6% year-over-year, with net profit attributable to shareholders surging 402.3% to RMB 241 million. Gross margin expanded from 74.4% to 79.3%. The pre-clinical segment generated RMB 723 million in revenue, up 57.9%, with innovative animal model sales rising 62.4% to RMB 446 million. The antibody discovery business posted RMB 218 million in revenue at a 92.8% gross margin, reflecting the company's AI and automation-powered platform monetization.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1177151029?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-09-21 14:13","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1177151029","market":"hk","top_or_hot":-1,"title":"Movement Alert｜BIOCYTOGEN-B Rises 9.63% in Regular Trading, AI Pharma Catalysts and Robust H1 Earnings Drive Rally","media":"Market Focus","content":"<p><p>On September 21, BIOCYTOGEN-B rose 9.63% in regular trading, trading at HKD 67.1/share, with turnover of HKD 205 million. The rally was fueled by intensifying AI drug discovery policy catalysts and the resonance of the company's outstanding first-half financial performance.</p><p>On the industry front, AI pharma policy and partnership catalysts have landed in rapid succession, with CXO sector sentiment firmly trending upward. Broker research notes that H1 domestic CXO sector revenue and net profit grew 24.5% and 52.7% year-over-year respectively, with order backlogs and new signings recovering broadly while leading firms raised full-year guidance.</p><p>On the earnings front, BIOCYTOGEN-B reported H1 revenue of RMB 941 million, up 51.6% year-over-year, with net profit attributable to shareholders surging 402.3% to RMB 241 million. Gross margin expanded from 74.4% to 79.3%. The pre-clinical segment generated RMB 723 million in revenue, up 57.9%, with innovative animal model sales rising 62.4% to RMB 446 million. The antibody discovery business posted RMB 218 million in revenue at a 92.8% gross margin, reflecting the company's AI and automation-powered platform monetization.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜BIOCYTOGEN-B Rises 9.63% in Regular Trading, AI Pharma Catalysts and Robust H1 Earnings Drive Rally</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜BIOCYTOGEN-B Rises 9.63% in Regular Trading, AI Pharma Catalysts and Robust H1 Earnings Drive Rally\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-09-21 14:13</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On September 21, BIOCYTOGEN-B rose 9.63% in regular trading, trading at HKD 67.1/share, with turnover of HKD 205 million. The rally was fueled by intensifying AI drug discovery policy catalysts and the resonance of the company's outstanding first-half financial performance.</p><p>On the industry front, AI pharma policy and partnership catalysts have landed in rapid succession, with CXO sector sentiment firmly trending upward. Broker research notes that H1 domestic CXO sector revenue and net profit grew 24.5% and 52.7% year-over-year respectively, with order backlogs and new signings recovering broadly while leading firms raised full-year guidance.</p><p>On the earnings front, BIOCYTOGEN-B reported H1 revenue of RMB 941 million, up 51.6% year-over-year, with net profit attributable to shareholders surging 402.3% to RMB 241 million. Gross margin expanded from 74.4% to 79.3%. The pre-clinical segment generated RMB 723 million in revenue, up 57.9%, with innovative animal model sales rising 62.4% to RMB 446 million. The antibody discovery business posted RMB 218 million in revenue at a 92.8% gross margin, reflecting the company's AI and automation-powered platform monetization.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02315","symbol_name":"百奥赛图-B","start_time":0,"source_url":"","article_id":"1177151029","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1177151029","pubTimestamp":1789971237,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On September 21, BIOCYTOGEN-B rose 9.63% in regular trading, trading at HKD 67.1/share, with turnover of HKD 205 million. The rally was fueled by intensifying AI drug discovery policy catalysts and...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02315":"百奥赛图-B"},"translate_title":"走势警报|BIOCYTOGEN-B 常规交易中上涨 9.63%，AI Pharma 催化剂和强劲的上半年盈利推动上涨","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02315":1},"content_text":"On September 21, BIOCYTOGEN-B rose 9.63% in regular trading, trading at HKD 67.1/share, with turnover of HKD 205 million. The rally was fueled by intensifying AI drug discovery policy catalysts and the resonance of the company's outstanding first-half financial performance.On the industry front, AI pharma policy and partnership catalysts have landed in rapid succession, with CXO sector sentiment firmly trending upward. Broker research notes that H1 domestic CXO sector revenue and net profit grew 24.5% and 52.7% year-over-year respectively, with order backlogs and new signings recovering broadly while leading firms raised full-year guidance.On the earnings front, BIOCYTOGEN-B reported H1 revenue of RMB 941 million, up 51.6% year-over-year, with net profit attributable to shareholders surging 402.3% to RMB 241 million. Gross margin expanded from 74.4% to 79.3%. The pre-clinical segment generated RMB 723 million in revenue, up 57.9%, with innovative animal model sales rising 62.4% to RMB 446 million. The antibody discovery business posted RMB 218 million in revenue at a 92.8% gross margin, reflecting the company's AI and automation-powered platform monetization.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1177151029","isCrawlerRequest":true}